Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Nilotinib is a second-generation tyrosine kinase inhibitor that has been approved for the first-line treatment of chronic-phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib versus imatinib (ENESTnd). Apart from this registration study, very few data a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Haematologica
Главные авторы: Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Levato, Luciano, D’Adda, Mariella, Stagno, Fabio, Tiribelli, Mario, Salvucci, Marzia, Fava, Carmen, Martino, Bruno, Cedrone, Michele, Bocchia, Monica, Trabacchi, Elena, Cavazzini, Francesco, Usala, Emilio, Rossi, Antonella Russo, Bochicchio, Maria Teresa, Soverini, Simona, Alimena, Giuliana, Cavo, Michele, Pane, Fabrizio, Martinelli, Giovanni, Saglio, Giuseppe, Baccarani, Michele, Rosti, Gianantonio
Формат: Artigo
Язык:Inglês
Опубликовано: Ferrata Storti Foundation 2015
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800682/
https://ncbi.nlm.nih.gov/pubmed/26113419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.129221
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы